JP7205940B2 - Solid phase reaction chip and measurement method using the same - Google Patents

Solid phase reaction chip and measurement method using the same Download PDF

Info

Publication number
JP7205940B2
JP7205940B2 JP2021502126A JP2021502126A JP7205940B2 JP 7205940 B2 JP7205940 B2 JP 7205940B2 JP 2021502126 A JP2021502126 A JP 2021502126A JP 2021502126 A JP2021502126 A JP 2021502126A JP 7205940 B2 JP7205940 B2 JP 7205940B2
Authority
JP
Japan
Prior art keywords
substance
phase reaction
reaction chip
measured
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021502126A
Other languages
Japanese (ja)
Other versions
JPWO2020171158A1 (en
Inventor
昭雄 中原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PARTNER FIRM CO., LTD.
Original Assignee
PARTNER FIRM CO., LTD.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PARTNER FIRM CO., LTD. filed Critical PARTNER FIRM CO., LTD.
Publication of JPWO2020171158A1 publication Critical patent/JPWO2020171158A1/en
Application granted granted Critical
Publication of JP7205940B2 publication Critical patent/JP7205940B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00Apparatus for enzymology or microbiology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00Apparatus for enzymology or microbiology
    • C12M1/34Measuring or testing with condition measuring or sensing means, e.g. colony counters
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N21/78Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N37/00Details not covered by any other group of this subclass
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/04Closures and closing means
    • B01L2300/041Connecting closures to device or container
    • B01L2300/042Caps; Plugs
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/08Geometry, shape and general structure
    • B01L2300/0803Disc shape

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Sustainable Development (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Description

本発明は、固相反応チップ及びこれを用いた測定方法に関するものである。 TECHNICAL FIELD The present invention relates to a solid phase reaction chip and a measurement method using the same.

気管支喘息、アレルギー性鼻炎、蕁麻疹、又はアナフィラキシーショック等の疾患を引き起こすI型アレルギーは、特定の抗原(アレルゲン)とそれに対するIgE抗体との過剰反応により引き起こされることが知られている。病院等の各診療現場においては、アレルギー疾患の原因である原因アレルゲンを特定する上で、検体液中に含まれるIgE抗体を検出する検査がなされている。現在、検体液中に含まれるアレルゲン特異的IgE抗体を検出する手法としては、免疫蛍光法を測定原理とするCAPや、免疫化学発光法を測定原理とするMASTと呼ばれる手法等が用いられている。 Type I allergy, which causes diseases such as bronchial asthma, allergic rhinitis, urticaria, or anaphylactic shock, is known to be caused by an excessive reaction between a specific antigen (allergen) and its IgE antibody. In clinical practice sites such as hospitals, tests are performed to detect IgE antibodies contained in test fluids in order to identify causative allergens that cause allergic diseases. Currently, methods for detecting allergen-specific IgE antibodies contained in sample liquids include CAP, which uses immunofluorescence as its measurement principle, and MAST, which uses immunochemiluminescence as its measurement principle. .

ところで、従来から、検体液中に含まれる、核酸、タンパク質、糖脂質といった測定対象物質を効率良く検出するために、当該測定対象物質と特異的結合能を有する結合物質を固相上に固定化し、当該固相上において結合物質に結合した測定対象物質の検出までを行う固相反応チップが用いられている。固相反応チップは、生化学の分野では、バイオチップとも呼ばれ、例えば、mRNAチップ、cDNAチップ、マイクロPCRチップ、プロテインチップ等が知られている。 By the way, conventionally, in order to efficiently detect target substances such as nucleic acids, proteins, and glycolipids contained in a sample liquid, a binding substance having specific binding ability with the target substances is immobilized on a solid phase. , a solid-phase reaction chip is used that performs up to detection of a substance to be measured bound to a binding substance on the solid phase. Solid-phase reaction chips are also called biochips in the field of biochemistry, and known examples include mRNA chips, cDNA chips, micro PCR chips, and protein chips.

近年、アレルギー疾患の診断に対しても、抗原抗体反応を用いた免疫分析マイクロチップが提案されており、例えば、特許文献1には、多種のアレルゲンの抗原を互いに独立した即ち隔置したスポットとして搭載したバイオチップを用いて、検体液の採取後に、検体液と抗原との反応検出過程を自動化し、且つ迅速に測定結果を得ることができるとするバイオチップの分析方法が開示されている。 In recent years, immunological analysis microchips using antigen-antibody reactions have been proposed for the diagnosis of allergic diseases. Disclosed is a biochip analysis method that uses a mounted biochip to automate the process of detecting a reaction between a sample liquid and an antigen after collection of the sample liquid, and to obtain measurement results quickly.

従来技術であるCAPは、原則的に1種のアレルゲンごとに測定を行う単項目法であり、測定ごとに検体液が必要となるため、被験者の肉体的負担が大きく、また測定に係るスループットも良くない。一方、MASTは、例えば、30種程度のアレルゲンに対して一度に測定を行う多項目法である。単項目法に比べて同時に測定可能なアレルゲン数は多いものの、操作が煩雑であり、測定結果が得られるまでに5時間程度の時間を要するものである。 CAP, which is a conventional technology, is a single-item method in which measurement is performed for each allergen in principle, and because a sample liquid is required for each measurement, the physical burden on the subject is large, and the throughput related to measurement is also low. not good. On the other hand, MAST is a multi-item method in which, for example, about 30 kinds of allergens are measured at once. Although the number of allergens that can be measured simultaneously is larger than that of the single item method, the operation is complicated and it takes about 5 hours to obtain measurement results.

また、上記特許文献1に記載の技術では、洗浄ノズル、抗体ノズル、試薬ノズルといった各ノズルから供給された各液を吸引するための吸引ノズルが必要であり、各液の吸引が完了するまでに時間を要するとともに、吸引ポンプの不調による吸引力不足や、吸引ノズルに付着した付着物がバイオチップに付着しコンタミネーションを引き起こす恐れもあった。 Further, the technique described in Patent Document 1 requires a suction nozzle for sucking each liquid supplied from each nozzle such as a washing nozzle, an antibody nozzle, and a reagent nozzle. In addition to the time required, there was also the risk of insufficient suction power due to malfunction of the suction pump, and the possibility of contamination due to deposits adhering to the suction nozzle adhering to the biochip.

このような実状に鑑み、本願出願人は、第1の基台部と第2の基台部とが積層されることにより形成される回転体の外周に吸液部材を備え、これを収容するカバー部材からなる固相反応チップを開発し、これを特許出願した(特許文献2)。特許文献2に係る発明は、第2の基台部の第1の基台部に対峙する面に、検体液に含まれる測定対象物質に対して特異的結合能を有する複数の結合物質を固定化することにより、少量の検体液での同時多項目測定を実現可能としたものであり、特許文献2に係る発明によれば、迅速に且つ簡便な操作で検体液中に含まれる測定対象物質を検出することが可能となる。 In view of such a situation, the applicant of the present application provided a liquid absorbing member on the outer periphery of the rotating body formed by laminating the first base portion and the second base portion, and accommodated the liquid absorbing member. A solid-phase reaction chip consisting of a cover member was developed and applied for a patent (Patent Document 2). The invention according to Patent Document 2 fixes a plurality of binding substances having specific binding ability to the substance to be measured contained in the specimen liquid on the surface of the second base facing the first base. This makes it possible to perform simultaneous multi-item measurement with a small amount of sample liquid. can be detected.

特開2011-13000号公報Japanese Patent Application Laid-Open No. 2011-13000 特開2016-200431号公報JP 2016-200431 A 特許第6107244号Patent No. 6107244 国際公開WO2018/056454号International publication WO2018/056454

特許文献2に係る固相反応チップでは、第1の基台部と第2の基台部とが積層されることにより形成される回転体を収容するカバー部材が必要となる。カバー部材は、固相反応チップ外形を形成するとともに、吸液部材を介して回転体を保持する役目を担っている。しかしながら、実験を重ねた結果、回転体は高速での回転に伴いカバー部材内部において変位し、測定精度に影響を与えていることが明らかとなった。加えて、円形の回転体は円環状に形成された吸液部材と面接触しているため、その接触面において液だまりが発生し、吸液能力が低下するといった問題もあった。 The solid-phase reaction chip according to Patent Document 2 requires a cover member that accommodates a rotating body formed by laminating the first base portion and the second base portion. The cover member forms the outer shape of the solid-phase reaction chip and also serves to hold the rotating body via the liquid-absorbing member. However, as a result of repeated experiments, it became clear that the rotating body is displaced inside the cover member as it rotates at high speed, which affects the measurement accuracy. In addition, since the circular rotating body is in surface contact with the liquid absorbing member formed in an annular shape, there is also a problem that liquid pools occur on the contact surface, and the liquid absorbing ability is lowered.

本発明はこのような問題を解決するためになされたものであり、本発明の課題は、内部に吸液部材を備えた固相反応チップの欠点を克服し、迅速に且つ簡便な操作で検体液中に含まれる測定対象物質を精度よく検出することが可能な固相反応チップ及びこれを用いた測定方法を提供することである。 The present invention has been made to solve such problems, and an object of the present invention is to overcome the drawbacks of the solid-phase reaction chip having a liquid-absorbing member inside, and to rapidly and simply operate the sample. An object of the present invention is to provide a solid-phase reaction chip capable of accurately detecting a substance to be measured contained in a liquid, and a measurement method using the same.

上記課題を解決するために、本発明に係る固定反応チップは、上蓋部材と下蓋部材とが嵌合一体化することにより回転体として形成される固相反応チップであって、前記上蓋部材又は前記下蓋部材の何れかの内側底面側に設けられ、検体液に含まれる測定対象物質に対して特異的結合能を有する複数の結合物質を固定化する固定化部と、前記上蓋部材に設けられ、前記固定化部表面に前記検体液を供給する開口部と、前記固定化部外側に設けられ、前記開口部を介して供給された前記検体液を吸液する吸液部とを有し、前記固定化部は、対峙する内側底面方向側に隆起した隆起部により区分された複数の固定化領域を有し、それぞれの固定化領域にはスポットがn×n列(nは2乃至6の整数)となるように配列され、それぞれのスポットは窪みが形成されて前記結合物質が固定可能とされ、各固定化領域の外縁部には少なくとも1つの頂点が含まれ、各固定化領域は回転対称に形成されることを特徴としている。
In order to solve the above problems, a fixed reaction chip according to the present invention is a solid-phase reaction chip formed as a rotating body by fitting and integrating an upper lid member and a lower lid member, wherein the upper lid member or an immobilizing section provided on the inner bottom surface side of any of the lower lid members for immobilizing a plurality of binding substances having specific binding ability to a substance to be measured contained in the sample liquid; and provided on the upper lid member. an opening for supplying the sample liquid to the surface of the immobilizing portion; and a liquid absorbing portion provided outside the immobilizing portion for absorbing the sample liquid supplied through the opening. , the immobilization part has a plurality of immobilization areas separated by raised parts that protrude toward the inner bottom surface facing each other, and each immobilization area has n×n rows of spots (where n is 2 to 6). an integer of ), each spot is recessed so that the binding substance can be immobilized, the outer edge of each immobilization region includes at least one vertex , and each immobilization region is It is characterized by being rotationally symmetrical .

また、本発明に係る測定方法は、上記固相反応チップに対して、前記開口部を介して前記検体液を導入し、前記測定対象物質と前記結合物質とを結合させる結合ステップと、前記結合物質に結合した前記測定対象物質に対して特異的結合能を有し酵素活性を備えた生理活性物質を含む反応液を添加する添加ステップと、前記開口部を介して洗浄液を導入後、固相反応チップを所定の回転数で回転させることで前記洗浄液を除去する除去ステップと、前記生理活性物質における前記酵素活性を測定する測定ステップとを備えることを特徴としている。 Further, the measurement method according to the present invention includes a binding step of introducing the sample liquid through the opening into the solid phase reaction chip to bind the substance to be measured and the binding substance; an addition step of adding a reaction solution containing a physiologically active substance having an ability to specifically bind to the substance to be measured and having enzymatic activity with respect to the substance to be measured; The method is characterized by comprising a removing step of removing the washing liquid by rotating the reaction chip at a predetermined number of revolutions, and a measuring step of measuring the enzymatic activity in the physiologically active substance.

さらに、本発明に係る測定方法は、上記固相反応チップに対して、前記開口部を介して前記検体液を導入し、前記測定対象物質と前記固定化部に固定化された前記結合物質とを結合させる第1の結合ステップと、前記測定対象物質に対して特異的結合能を有し、シグナル生成物質により標識された標識化物質を前記第1の結合ステップにて前記結合物質に結合した前記測定対象物質に結合させる第2の結合ステップと、前記シグナル生成物質により生じたシグナルを測定する測定ステップとを備えることを特徴としている。 Further, in the measurement method according to the present invention, the sample liquid is introduced into the solid-phase reaction chip through the opening, and the substance to be measured and the binding substance immobilized on the immobilizing portion are separated from each other. and a labeled substance having specific binding ability to the substance to be measured and labeled with a signal-generating substance was bound to the binding substance in the first binding step It is characterized by comprising a second binding step of binding to the substance to be measured, and a measuring step of measuring a signal generated by the signal-generating substance.

本発明によれば、内部に吸液部材を備えた固相反応チップの欠点を克服し、迅速に且つ簡便な操作で検体液中に含まれる測定対象物質を精度よく検出することが可能な固相反応チップ及びこれを用いた測定方法を提供することができる。 ADVANTAGE OF THE INVENTION According to the present invention, the drawbacks of the solid-phase reaction chip having a liquid-absorbing member inside can be overcome, and the solid-phase reaction chip can be rapidly and simply operated to accurately detect the substance to be measured contained in the sample liquid. A phase reaction chip and a measurement method using the same can be provided.

本実施形態に係る固相反応チップ100の概観を説明するための斜視図である。1 is a perspective view for explaining an overview of a solid phase reaction chip 100 according to this embodiment; FIG. 固相反応チップ100を構成する各部材の部品図である。4 is a component diagram of each member constituting the solid-phase reaction chip 100. FIG. (a)は上蓋部材10を内側底面11側に見た場合の平面図であり、(b)は上蓋部材10の側面断面図である。(a) is a plan view of the upper lid member 10 viewed from the inner bottom surface 11 side, and (b) is a side sectional view of the upper lid member 10. FIG. (a)は下蓋部材20を内側底面21側に見た場合の平面図であり、(b)は下蓋部材20の側面断面図である。(a) is a plan view when the lower lid member 20 is viewed from the inner bottom surface 21 side, and (b) is a side sectional view of the lower lid member 20. FIG. 図1で示した固相反応チップ100の側面断面図である。FIG. 2 is a side sectional view of the solid-phase reaction chip 100 shown in FIG. 1; 本実施形態に係る測定方法を説明するフローチャートである。It is a flow chart explaining a measuring method concerning this embodiment. 自動測定装置200の構成例を説明するブロック図である。2 is a block diagram illustrating a configuration example of an automatic measurement device 200; FIG. (a)は変形例に係る上蓋部材101を説明する平面図であり、(b)は変形例に係る下蓋部材301を説明する平面図である。(a) is a plan view explaining an upper lid member 101 according to a modification, and (b) is a plan view explaining a lower lid member 301 according to a modification. (a)は変形例に係る上蓋部材102を説明する平面図であり、(b)は変形例に係る下蓋部材302を説明する平面図である。(a) is a plan view explaining an upper lid member 102 according to a modification, and (b) is a plan view explaining a lower lid member 302 according to a modification. (a)は変形例に係る固相反応チップ50を説明する斜視図であり、(b)は変形例に係る固相反応チップ60を説明する斜視図である。(a) is a perspective view explaining a solid phase reaction chip 50 according to a modification, and (b) is a perspective view explaining a solid phase reaction chip 60 according to a modification. 本実施形態に係る測定方法にて測定した比色スポットの発色状態を示す図である。FIG. 4 is a diagram showing the color development state of colorimetric spots measured by the measurement method according to the present embodiment. 本実施形態に係る測定方法にて測定した比色スポットの発色状態を示す図である。FIG. 4 is a diagram showing the color development state of colorimetric spots measured by the measurement method according to the present embodiment.

以下、本発明を実施するための形態について図面を参照して説明する。なお、本発明は、以下の記述に限定されるものではなく、本発明の要旨を逸脱しない範囲において適宜変更可能である。また、図面は模式的なものであり、各寸法の比率等は現実のものとは異なることがある。具体的な寸法は以下の説明を参酌して判断すべきものである。また、図面相互間においても互いの寸法の関係や比率が異なる部分が含まれていることは無論である。 BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, embodiments for carrying out the present invention will be described with reference to the drawings. It should be noted that the present invention is not limited to the following description, and can be modified as appropriate without departing from the gist of the present invention. Also, the drawings are schematic, and the ratio of each dimension may differ from the actual one. Specific dimensions should be determined with reference to the following description. In addition, it goes without saying that there are portions with different dimensional relationships and ratios between the drawings.

本発明に係る固相反応チップは、上蓋部材と下蓋部材とが嵌合一体化することにより回転体として形成される固相反応チップであって、上蓋部材又は下蓋部材の何れかの内側底面側に設けられ、検体液に含まれる測定対象物質に対して特異的結合能を有する複数の結合物質を固定化する固定化部と、上蓋部材に設けられ、固定化部表面に検体液を供給する開口部と、固定化部外側に設けられ、開口部を介して供給された検体液を吸液する吸液部とを有し、固定化部は、対峙する内側底面方向側に隆起した隆起部により区分された複数の固定化領域を有し、各固定化領域の外縁部には少なくとも1つの頂点が含まれるものである。以下詳細に説明する。 A solid-phase reaction chip according to the present invention is a solid-phase reaction chip formed as a rotating body by fitting and integrating an upper lid member and a lower lid member. An immobilization section provided on the bottom side for immobilizing a plurality of binding substances having specific binding ability to the substance to be measured contained in the sample liquid; It has an opening for supply and a liquid absorption part provided outside the immobilization part for absorbing the sample liquid supplied through the opening, and the immobilization part protrudes toward the opposite inner bottom surface. It has a plurality of immobilization areas separated by ridges, each immobilization area including at least one apex at its outer edge. A detailed description will be given below.

図1は、本実施形態に係る固相反応チップ100の概観を説明するための斜視図であり、図2は、固相反応チップ100を構成する各部材の部品図である。本実施形態に係る固相反応チップ100は、上蓋部材10と、上蓋部材10と嵌合一体化し、上蓋部材10とともに回転体を形成する下蓋部材20とを備え、上蓋部材10と下蓋部材20とが嵌合することにより形成される内部空間30には、開口部14を介して供給された検体液、反応液、洗浄液等(以下、単に液体と称することがある)を回収する吸液部材40が、後述する固定化部23の外周27に沿って設けられている。なお、以下の説明では、下蓋部材20の内側底面21側に固定化部23が設けられた構成について説明するが、これとは逆に、上蓋部材10の内側底面11側に固定化部23を設ける構成としても構わない。 FIG. 1 is a perspective view for explaining an overview of the solid phase reaction chip 100 according to this embodiment, and FIG. 2 is a component diagram of each member constituting the solid phase reaction chip 100. A solid-phase reaction chip 100 according to this embodiment comprises an upper cover member 10 and a lower cover member 20 which is integrally fitted with the upper cover member 10 and forms a body of rotation together with the upper cover member 10. The upper cover member 10 and the lower cover member In the internal space 30 formed by the fitting of the 20, a liquid absorbing liquid for collecting the sample liquid, the reaction liquid, the washing liquid, etc. (hereinafter sometimes simply referred to as liquid) supplied through the opening 14 A member 40 is provided along an outer circumference 27 of the immobilizing portion 23, which will be described later. In the following description, a configuration in which the fixing portion 23 is provided on the inner bottom surface 21 side of the lower lid member 20 will be described. may be provided.

図3(a)は、上蓋部材10を内側底面11側に見た場合の平面図であり、図3(b)は、上蓋部材10の側面断面図である。本実施形態に係る上蓋部材10は、略正円の形状を有し、内側底面11の周縁(円周)に沿って、下蓋部材20との嵌合が可能となるように上蓋嵌合壁12が立設されている。上蓋部材10の内側底面11には、下蓋部材20の固定化部23の平面視形状と同じ四角形状を有し、固定化部表面24に対峙する固定化部対峙面13が形成されている。固定化部対峙面13は、後述する固定化部表面24上に設けられた隆起部26が当接することにより、固定化部表面24との間で空隙を形成し、開口部14を介して供給された液体を固定化部表面24上に展開可能とする。なお、固定化部対峙面13は、図3(b)に示すように、内側底面11から所定の突出幅aを持って形成することも可能であるし、内側底面11表面上に平滑面として直接形成することも可能である。また、固定化部対峙面13の平面視形状は固定化部23全体の平面視形状と同一形状とすることも可能であるし、異なる形状としても構わない。開口部14は、上蓋部材10の表面略中央であって、下蓋部材20の回転軸と同軸上に設けられている。開口部14は、テーパー形状に形成された開口部分を有し、固定化部対峙面13の面上に導通している。 3(a) is a plan view of the upper lid member 10 viewed from the inner bottom surface 11 side, and FIG. 3(b) is a side sectional view of the upper lid member 10. FIG. The upper lid member 10 according to the present embodiment has a substantially perfect circular shape, and has an upper lid fitting wall along the peripheral edge (circumference) of the inner bottom surface 11 so that it can be fitted with the lower lid member 20 . 12 are erected. The inner bottom surface 11 of the upper lid member 10 is formed with a fixing portion facing surface 13 that has the same square shape as the fixing portion 23 of the lower lid member 20 in plan view and faces the fixing portion surface 24 . . The immobilizing portion facing surface 13 forms a gap with the immobilizing portion surface 24 by abutting a protuberant portion 26 provided on the immobilizing portion surface 24 to be described later, and supplies the liquid through the opening 14 . The applied liquid can be developed on the immobilizing part surface 24 . In addition, as shown in FIG. 3B, the fixing portion facing surface 13 can be formed with a predetermined protrusion width a from the inner bottom surface 11, or can be formed as a smooth surface on the surface of the inner bottom surface 11. Direct formation is also possible. In addition, the plane view shape of the immobilizing portion facing surface 13 may be the same shape as the plane view shape of the entire immobilizing portion 23, or may be a different shape. The opening 14 is provided substantially at the center of the surface of the upper lid member 10 and coaxially with the rotating shaft of the lower lid member 20 . The opening 14 has a taper-shaped opening and is electrically connected to the immobilizing portion facing surface 13 .

図4(a)は、下蓋部材20を内側底面21側に見た場合の平面図であり、図4(b)は、下蓋部材20の側面断面図である。本実施形態に係る下蓋部材20は、上蓋部材10と同形状の略正円の形状を有し、内側底面21の周縁(円周)よりも内側に、上蓋部材10との嵌合が可能となるように下蓋嵌合壁22が立設されている。下蓋部材20の内側底面21には、平面視形状が四角形状の固定化部23が形成されている。固定化部23の固定化部表面24には、測定対象物質に対して特異的結合能を有する複数の結合物質を固定化する固定化領域25が形成されている。本実施形態においては、固定化部表面24は対峙する上蓋部材10の内側底面11方向側に隆起した隆起部26によって4つの固定化領域25に区分されている。前述したように、固定化部表面24上に設けられた隆起部26が上蓋部材10の固定化部対峙面13に当接することにより、固定化部表面24と固定化部対峙面13との間で空隙が形成され、開口部14を介して供給された液体は当該空隙(固定化領域25)に導入されることになる。隆起部26によって区切られた各固定化領域25の外縁部28には少なくとも1つの頂点230が含まれる。本実施形態においては、各固定化領域25の外縁部28に内角度が90°を示す1つの頂点230が設けられ、固定化部23の全体の平面視形状として四角形状を有する固定化部23の例について示している。なお、固定化領域25の外縁部28に含まれる頂点は30°~162°の内角度を示すものとし、頂点数は1つ以上であれば特に限定はされることない。そして、固定化部23に含まれる4つの固定化領域25の平面視形状は全て同一形状とし、回転対となるように構成されることが好ましい。固定化部23に含まれる4つの固定化領域25をこのような形状とすることにより、固相反応チップ100を回転させた際に安定した回転状態を得ることができ、開口部14を介して供給された液体を均一に固定化部表面24と固定化部対峙面13との間の空隙に展開することができる。固定化領域25には、1領域当たり、直径100μm~1mm程度の大きさのスポット250が1領域当たり4×4列(16スポット)で形成されている。なお、固定化領域25に固定化される結合物質の数は、上記64種に限定されるものではなく、例えば、2×2列(合計16種)~6×6列(合計144種)というように測定種目に応じて適宜変更することができる。また、結合物質の固定化方法も上記スポットによるものではなく、各固定化位置に対応する箇所に設けた、例えば、U底(球面状)、V底、平底(丸型、角型)状等の底部を有する窪み(ウェル)に結合物質を直接的又は間接的に固定化させる方法を採用しても構わない。
4A is a plan view of the lower lid member 20 viewed from the inner bottom surface 21 side, and FIG. 4B is a side sectional view of the lower lid member 20. FIG. The lower lid member 20 according to the present embodiment has the same shape as the upper lid member 10, which is substantially a perfect circle, and can be fitted with the upper lid member 10 inside the peripheral edge (circumference) of the inner bottom surface 21. The lower lid fitting wall 22 is erected so as to be. An inner bottom surface 21 of the lower lid member 20 is formed with a fixed portion 23 having a square shape in plan view. An immobilization region 25 is formed on the immobilization surface 24 of the immobilization part 23 to immobilize a plurality of binding substances having specific binding ability to the substance to be measured. In this embodiment, the immobilizing portion surface 24 is divided into four immobilizing regions 25 by raised portions 26 that protrude toward the inner bottom surface 11 of the upper lid member 10 facing each other. As described above, the raised portion 26 provided on the immobilization portion surface 24 abuts against the immobilization portion-facing surface 13 of the upper lid member 10, thereby providing a gap between the immobilization portion surface 24 and the immobilization portion-facing surface 13. A gap is formed in , and the liquid supplied through the opening 14 is introduced into the gap (immobilization region 25). The outer edge 28 of each immobilization region 25 bounded by ridges 26 includes at least one vertex 230 . In this embodiment, one vertex 230 having an inner angle of 90° is provided on the outer edge portion 28 of each immobilization region 25, and the immobilization portion 23 has a rectangular shape as a plan view of the entire immobilization portion 23. It shows an example of Note that the vertices included in the outer edge portion 28 of the immobilization region 25 indicate an inner angle of 30° to 162°, and the number of vertices is not particularly limited as long as it is one or more. It is preferable that the four immobilizing regions 25 included in the immobilizing part 23 have the same planar shape and are rotationally symmetrical . By forming the four immobilization regions 25 included in the immobilization part 23 into such a shape, a stable rotation state can be obtained when the solid-phase reaction chip 100 is rotated. The supplied liquid can be spread uniformly in the gap between the immobilizing portion surface 24 and the immobilizing portion facing surface 13 . In the immobilization region 25, spots 250 having a diameter of about 100 μm to 1 mm are formed in 4×4 rows (16 spots) per region. The number of binding substances immobilized in the immobilization region 25 is not limited to the 64 types described above, and may be, for example, 2×2 rows (total 16 types) to 6×6 rows (total 144 types). It can be changed as appropriate according to the type of measurement. In addition, the method of immobilizing the binding substance is not based on the above-mentioned spotting, but rather, a U-bottomed (spherical), V-bottomed, flat-bottomed (round or square) shape, etc., is provided at a location corresponding to each immobilization position. A method of directly or indirectly immobilizing a binding substance in a depression (well) having a bottom may be employed.

下蓋部材20の内側底面21上に設けた固定化部23の固定化領域25の外縁部28を上記形状とすることで、吸液部材40との接触面積を低減することが可能となり、その結果、液だまりの発生を軽減することができる。ところで、図4(b)に示すように、固定化部23の内側底面21からの突出幅bは、固定化部対峙面13との間に形成される空隙が所定の空隙幅となればその制限はなく、隆起部26の高さを考慮するとともに、上蓋部材10に形成された固定化部対峙面13の突出幅aに応じて適宜設定すればよい。 By forming the outer edge portion 28 of the immobilizing region 25 of the immobilizing portion 23 provided on the inner bottom surface 21 of the lower lid member 20 into the above shape, it is possible to reduce the contact area with the liquid absorbing member 40. As a result, it is possible to reduce the occurrence of liquid puddles. By the way, as shown in FIG. 4(b), the width b of the protrusion from the inner bottom surface 21 of the immobilization portion 23 can be adjusted if the gap formed between the immobilization portion facing surface 13 and the immobilization portion facing surface 13 has a predetermined gap width. There is no limitation, and the height of the protuberance 26 may be taken into account, and it may be appropriately set according to the protrusion width a of the fixing portion facing surface 13 formed on the upper lid member 10 .

図5は、図1で示した固相反応チップ100の側面断面図である。本実施形態においては、固定化部表面24と固定化部対峙面間13との間に形成される空隙の空隙幅cは、0.05mm~0.30mmの間とすることが好ましく、この中でも、空隙幅cを0.08mm~0.15mmの間とするのがより好ましい。なお、前述したように、空隙幅cは、固定化部23の突出幅b、固定化部対峙面13の突出幅a、及び隆起部26高さを調整することにより適宜変更することが可能であり、これにより空隙に供給される液体の液量を所望の液量とすることができる。 FIG. 5 is a side sectional view of the solid-phase reaction chip 100 shown in FIG. In this embodiment, the gap width c of the gap formed between the immobilizing part surface 24 and the immobilizing part facing surface 13 is preferably between 0.05 mm and 0.30 mm. , the gap width c is preferably between 0.08 mm and 0.15 mm. As described above, the gap width c can be changed as appropriate by adjusting the protrusion width b of the immobilizing portion 23, the protrusion width a of the immobilizing portion facing surface 13, and the height of the raised portion 26. Therefore, the amount of liquid supplied to the gap can be set to a desired amount.

上記構成を有する上蓋部材10及び下蓋部材20は、液体を透過させず、タンパク質等に対して非吸着性を有するものであれば特に限定されるものではなく、例えば、ポリエチレン、ポリカーボネート、ポリエチレンテレフタレート、塩化ビニル、ポリスチレン、ABS樹脂、ポリアミド、四フッ化エチレン、ポリプロピレン、不飽和ポリエステル、エポキシ等のプラスチック原料を用い、例えば、射出成形、インサート成形、ブロー成形、押出成形、圧縮成形、又はトランファー成形といった成形方法にて製造することができる。材質の色彩・透過性ついては特に限定はないが、上蓋部材10は透明性を有し、下蓋部材20は測定時の反射等を抑えるために非透過性であることが好ましい。そして、上蓋部材10と下蓋部材20との嵌合一体化は、特に制限はないが、上蓋部材10の上蓋嵌合壁12と下蓋部材20の下蓋嵌合壁22とを、超音波溶着、振動溶着、熱板溶着、高周波溶着、熱風溶着、レーザー溶着、溶接等の溶着・溶接、接着剤、接着テープ等の接着、タッピングネジ、ボルト及びナットを用いた機械締結等により接合することで嵌合一体化を図ることができる。 The upper lid member 10 and the lower lid member 20 having the above-described structure are not particularly limited as long as they are impermeable to liquid and have non-adsorptive properties for proteins and the like. Examples include polyethylene, polycarbonate, and polyethylene terephthalate. , vinyl chloride, polystyrene, ABS resin, polyamide, tetrafluoroethylene, polypropylene, unsaturated polyester, epoxy and other plastic materials, for example, injection molding, insert molding, blow molding, extrusion molding, compression molding, or transfer molding It can be manufactured by a molding method such as molding. Although there are no particular restrictions on the color and transparency of the material, it is preferable that the upper cover member 10 has transparency and the lower cover member 20 is non-transparent in order to suppress reflection during measurement. Although there is no particular limitation on the integration of the upper lid member 10 and the lower lid member 20, the upper lid fitting wall 12 of the upper lid member 10 and the lower lid fitting wall 22 of the lower lid member 20 are ultrasonically coupled. Joining by welding, vibration welding, hot plate welding, high frequency welding, hot air welding, laser welding, welding such as welding, adhesion of adhesives, adhesive tapes, etc., mechanical fastening using tapping screws, bolts and nuts, etc. can achieve fitting and integration.

ところで、上蓋部材10と下蓋部材20とが嵌合することにより形成される内部空間30に収容される吸液部材40は、細板状に形成された部材をそれぞれの両端部同士で接合した円環部材として形成することができ、固定化部23の外側(外周27)に沿って設けられる。吸液部材40は、回転に伴い発生する遠心力によって除去され液体を吸液するために設けられる。このような吸液部材40の製造に用いる材質としては、例えば、ポリエチレンテレフタレートやポリエチレンテレブチレート等のポリエステル系繊維、ポリエチレン、ポリプロピレン等のポリオレフィン系繊維、ポリウレタン、あるいはこれらを複合した複合繊維や、パルプ繊維、木綿繊維、麻繊維等の植物繊維、絹繊維、レーヨン繊維等の再生繊維といった繊維、織布、不織布、紙等の吸水・保水性に優れた材質を用いることができる。また、パルプ繊維やレーヨン繊維といったセルロースを主成分とするもの、木材パルプに酢酸を作用させて製したアセテート(アセチルセルロース)といった多糖類からなる多孔質マトリックスを用いることができる。 By the way, the liquid absorbing member 40 accommodated in the internal space 30 formed by fitting the upper lid member 10 and the lower lid member 20 is formed by joining thin plate-shaped members at both ends thereof. It can be formed as an annular member and is provided along the outside (periphery 27 ) of the immobilization portion 23 . The liquid absorbing member 40 is provided to absorb the liquid removed by the centrifugal force generated along with the rotation. Examples of materials used for manufacturing the absorbent member 40 include polyester fibers such as polyethylene terephthalate and polyethylene terebutylate; polyolefin fibers such as polyethylene and polypropylene; polyurethane; Materials having excellent water absorption and retention properties, such as fibers such as plant fibers such as pulp fibers, cotton fibers and hemp fibers, regenerated fibers such as silk fibers and rayon fibers, woven fabrics, non-woven fabrics and paper, can be used. In addition, it is possible to use cellulose-based materials such as pulp fibers and rayon fibers, and porous matrices composed of polysaccharides such as acetate (acetyl cellulose) produced by reacting wood pulp with acetic acid.

次に、本実施形態に係る固相反応チップ100を用いた測定方法について図6のフローチャートを用いて説明する。本測定法では、固相反応チップ100に対して、開口部14を介して検体液を導入し、測定対象物質と結合物質とを結合させる結合ステップと、結合物質に結合した測定対象物質に対して特異的結合能を有し酵素活性を備えた生理活性物質を含む反応液を添加する添加ステップと、固相反応チップを所定の回転速度で回転させることで反応液を除去する除去ステップと、生理活性物質における酵素活性を測定する測定ステップとを備えるものである。 Next, a measurement method using the solid phase reaction chip 100 according to this embodiment will be described with reference to the flow chart of FIG. In this measurement method, a sample liquid is introduced into the solid-phase reaction chip 100 through the opening 14 to bind the substance to be measured and the binding substance; an addition step of adding a reaction solution containing a physiologically active substance having specific binding ability and enzymatic activity, a removal step of removing the reaction solution by rotating the solid-phase reaction chip at a predetermined rotation speed; and a measuring step of measuring the enzymatic activity in the physiologically active substance.

本実施形態に係る測定法では、測定対象物質をアレルゲンに特異的に結合するIgE抗体とした例について説明する。固定化部23の固定化部表面24の固定化領域25に結合物質として固定化される結合物質としてのアレルゲンとしては、特に限定されることはないが、例えば、ハウスダスト1(2)、ヤケヒョウヒダニ、スギ、ヒノキ、ハンノキ(属)、シラカンバ(属)、カモガヤ、ブタクサ、ヨモギ、アルテルナリア、アスペルギルス、マラセチア(属)、ネコ(フケ)、イヌ(フケ)、ゴキブリ、ガ、ラテックス等の吸入系・その他のアレルゲン、牛乳、卵白、オポムコイド、米、コムギ(実)、ソバ、大豆、ピーナッツ、リンゴ、キウイ、ゴマ、牛肉、鶏肉、エビ、カニ、サバ、サケ、マグロ等の食物系アレルゲンといった、医療機関等でアレルゲン検査項目として受診可能なものであれば如何なるアレルゲンも選択可能である。 In the measurement method according to this embodiment, an example in which an IgE antibody that specifically binds to an allergen is used as a substance to be measured will be described. The allergen as a binding substance immobilized as a binding substance in the immobilization region 25 of the immobilization portion surface 24 of the immobilization portion 23 is not particularly limited, but for example, house dust 1 (2), Dermatophagoides farinae , Japanese cedar, cypress, alder (genus), birch (genus), Dactylis, ragweed, mugwort, Alternaria, Aspergillus, Malassezia (genus), cat (dandruff), dog (dandruff), cockroach, moth, latex, etc.・Other allergens such as milk, egg white, opomucoid, rice, wheat (fruit), buckwheat, soybeans, peanuts, apples, kiwi, sesame, beef, chicken, shrimp, crab, mackerel, salmon, tuna, etc. Any allergen can be selected as long as it can be examined as an allergen test item at a medical institution or the like.

固定化領域25へのアレルゲンの固定化は、一般的に用いられる物理的吸着又は化学的結合によって行うことができる。例えば、測定項目のアレルゲンを含むアレルゲン溶液を固定化領域25の所望の位置、又は例えば、U底(球面状)、V底、平底(丸型、角型)状等の底部を有する窪み(ウェル)にスポッティング又はスタンプすることで当該アレルゲンを固定化領域25に固定化する。この場合、アレルゲンを直接固定化領域25に固定させてもよいし、スペーサ物質を介してアレルゲンを固定化する形態としてもよい。本実施形態に係る固定化領域25には、合計で64か所のスポット位置が設けられているため、各スポットに異なるアレルゲンを固定化することで、64種の測定項目を一度に測定することができる。 Immobilization of the allergen to the immobilization region 25 can be performed by generally used physical adsorption or chemical bonding. For example, an allergen solution containing an allergen of a measurement item is placed at a desired position in the immobilization region 25, or a recess (well) having a bottom such as a U bottom (spherical shape), a V bottom, or a flat bottom (round shape, square shape). ), the allergen is immobilized on the immobilization region 25 by spotting or stamping. In this case, the allergen may be directly immobilized on the immobilization region 25, or the allergen may be immobilized via a spacer substance. Since a total of 64 spot positions are provided in the immobilization region 25 according to the present embodiment, 64 types of measurement items can be measured at once by immobilizing different allergens in each spot. can be done.

また、測定対象物質としてのIgE抗体に対して特異的結合能の有し酵素活性を備えた生理活性物質としては、特に限定はされないが、例えば、アルカリ性ホスファターゼ、β-ガラクトシダーゼ、グルコースオキシダーゼ、ウレアーゼ、クレアチンキナーゼ、ウリカーゼ、グルコース-6-ホスフェートデヒドロゲナーゼ、ペルオキシダーゼ等で標識した抗IgE抗体を用いるのが好ましい。本実施形態では、西洋ワサビペルオキシダーゼ(HRP)で抗IgE抗体を標識したHRP標識抗体を用いた例について説明する。HRP標識抗体を用いた場合、生成されるシグナルは基質に依存して比色シグナル、化学発光シグナルとして得ることができる。比色シグナルの生成に用いられる基質としては、例えば、テトラメチルベンジジン及びその誘導体、o-フェニレンジアミン、トリアリールメタン類、イミダゾールロイコ色素類等を用いることができる。また、化学発光シグナルの生成には、例えば、アクリジニウム塩類、ジオキセタン類、ルシフェリン、ルシゲニン、塩化オキザリル等を挙げることができる。 In addition, the physiologically active substance having the ability to specifically bind to the IgE antibody as the substance to be measured and having enzymatic activity is not particularly limited, but examples thereof include alkaline phosphatase, β-galactosidase, glucose oxidase, urease, Anti-IgE antibodies labeled with creatine kinase, uricase, glucose-6-phosphate dehydrogenase, peroxidase or the like are preferably used. In this embodiment, an example using an HRP-labeled antibody obtained by labeling an anti-IgE antibody with horseradish peroxidase (HRP) will be described. When an HRP-labeled antibody is used, the generated signal can be obtained as a colorimetric signal or a chemiluminescent signal depending on the substrate. Substrates used to generate colorimetric signals include, for example, tetramethylbenzidine and its derivatives, o-phenylenediamine, triarylmethanes, imidazole leuco dyes, and the like. Examples of chemiluminescent signal generation include acridinium salts, dioxetanes, luciferin, lucigenin, oxalyl chloride, and the like.

固定化領域25にアレルゲンが固定化された下蓋部材20と上蓋部材10とから形成される内部空間30に吸液部材40を収納後、下蓋部材20と上蓋部材10とを嵌合一体化することで固相反応チップ100を構成する。 After the liquid absorbing member 40 is housed in the internal space 30 formed by the upper lid member 10 and the lower lid member 20 in which the allergen is immobilized in the immobilization region 25, the lower lid member 20 and the upper lid member 10 are fitted and integrated. By doing so, the solid phase reaction chip 100 is constructed.

そして、上蓋部材10の開口部14を介して検体液(30μl~60μl)を供給する(ステップS100)。検体液としては、全血、血清、血漿、涙液、尿、唾液、髄液等の生体試料から適宜選択することができる。開口部14に検体液が供給されると、当該検体液は、固定化領域25全域に展開され、各スポットに固定化された結合物質たるアレルゲンに特異的結合能を有するIgE抗体が結合する。このとき、固相反応チップ100は、35℃~40℃の範囲の温度環境下に置かれることが好ましい。例えば、37℃前後の温度維持が可能な恒温槽内において一連の操作を行うことで、アレルゲンに対しIgE抗体を効率良く結合させることができる。 Then, the specimen liquid (30 μl to 60 μl) is supplied through the opening 14 of the upper cover member 10 (step S100). The sample liquid can be appropriately selected from biological samples such as whole blood, serum, plasma, tears, urine, saliva, spinal fluid, and the like. When the sample liquid is supplied to the opening 14, the sample liquid is spread over the entire immobilization region 25, and the IgE antibody having specific binding ability binds to the allergen, which is the binding substance immobilized on each spot. At this time, the solid-phase reaction chip 100 is preferably placed in a temperature environment of 35.degree. C. to 40.degree. For example, the IgE antibody can be efficiently bound to the allergen by performing a series of operations in a constant temperature bath capable of maintaining a temperature of around 37°C.

次に、例えば、tween20等の界面活性剤を含む洗浄液(30μl~60μl)を開口部14を介して供給した後、所定の回転数(2000~2500rpm/min)にて回転させることで洗浄液を除去する(ステップS101)。 Next, for example, after supplying a washing liquid (30 μl to 60 μl) containing a surfactant such as tween 20 through the opening 14, the washing liquid is removed by rotating at a predetermined rotation speed (2000 to 2500 rpm/min). (step S101).

次に、ステップS102において、HRP標識抗体を含む反応液(30μl~60μl)を開口部14を介して供給する(ステップS102)。アレルゲンに結合したIgE抗体にHRP標識抗体を結合させた後、例えば、tween20等の界面活性剤を含む洗浄液(30μl~60μl)を開口部14を介して供給した後、所定の回転数(2000~2500rpm/min)にて回転させることで洗浄液を除去する(ステップS103)。 Next, in step S102, a reaction solution (30 μl to 60 μl) containing the HRP-labeled antibody is supplied through the opening 14 (step S102). After binding the HRP-labeled antibody to the IgE antibody bound to the allergen, for example, after supplying a washing solution (30 μl to 60 μl) containing a surfactant such as tween 20 through the opening 14, a predetermined number of rotations (2000 to The washing liquid is removed by rotating at 2500 rpm/min (step S103).

ステップS103での洗浄が完了後、テトラメチルベンジジン(TMB)等の基質を加え、比色シグナルを発したスポットをCCD等の撮像手段を用いて測定する(ステップS104)。 After the washing in step S103 is completed, a substrate such as tetramethylbenzidine (TMB) is added, and the spots emitting colorimetric signals are measured using imaging means such as CCD (step S104).

ところで、図6のフローチャートで説明した測定方法は手動によるものであるが、例えば、図7に示す構成を備えた自動測定装置200を用いることにより当該測定を自動的に行わせることができる。自動測定装置200は、少なくともセットされた試薬カートリッジから溶液を吸引・吐出することが可能な分注ユニット201と、固相反応チップ100を保持した状態で1分間当たり所定の回転数で回転させる遠心分離部202と、CCD等の撮像手段を備えた撮像部203と、タッチパネル等の入力手段や、装置情報若しくは測定結果等を表示するLCD(Liquid Crystal Display)等の表示手段を備えた操作部204と、撮像部203により撮像された画像(比色シグナル発光スポット等)を解析する画像解析部205と、画像解析部205による解析結果から測定結果を生成する測定結果生成部206と、これらを統括的に制御する制御部207とを備え、試薬カートリッジ又は固相反応チップ100の装置へのセット以外、検査員による実動作が不要となるように構成されている。 By the way, the measuring method described in the flow chart of FIG. 6 is performed manually, but the measurement can be automatically performed by using an automatic measuring device 200 having the configuration shown in FIG. 7, for example. The automatic measuring device 200 includes at least a dispensing unit 201 capable of aspirating and discharging a solution from a set reagent cartridge, and a centrifugal unit 201 that holds the solid-phase reaction chip 100 and rotates it at a predetermined number of revolutions per minute. A separating unit 202, an imaging unit 203 including an imaging unit such as a CCD, and an operation unit 204 including an input unit such as a touch panel and a display unit such as an LCD (Liquid Crystal Display) for displaying device information or measurement results. , an image analysis unit 205 that analyzes an image (colorimetric signal emission spot, etc.) captured by the imaging unit 203, a measurement result generation unit 206 that generates measurement results from the analysis results of the image analysis unit 205, and these are integrated It is equipped with a controller 207 that performs physical control, and is configured so that actual operations by the inspector are not required except for setting the reagent cartridge or solid-phase reaction chip 100 to the apparatus.

上記構成の自動測定装置200によれば、約20分程度で最終的な測定結果が得られるためスループットが高く、また、操作部204を介して表示される画面に従い直感的に操作を行うことができるため、熟練の技術を必要としないといった利点がある。また、装置自体も小型化することが可能であるため、臨床現場即時検査用の装置として適用させることも可能である。 According to the automatic measurement apparatus 200 configured as described above, the final measurement result can be obtained in about 20 minutes, so the throughput is high. Since it can be done, there is an advantage that a skilled technique is not required. In addition, since the device itself can be made smaller, it can be applied as a device for immediate examination at clinical sites.

なお、上記測定方法の説明においては、測定対象物質をアレルゲンに特異的に結合するIgE抗体とした例とし、固定化領域25に結合物質として固定化するものとしてアレルゲンの例について説明したが、本発明はこれに限定されるものではなく、測定対象物質を、例えば、ヒトパピローウィルス(HPV)に由来する遺伝子型とし、第2の基台部32の固定化領域32cに結合物質として固定化するものとしてHPVに由来するゲノムDNAプローブとすることも可能である。この場合、16型、18型、31型、33型、35型、39型、45型、51型、52型、56型、58型、59型、68型等の13種の高リスク型として分類されるHPVを検出する測定系として構築することも可能である。 In the above description of the measurement method, an example of an IgE antibody that specifically binds to an allergen is used as the substance to be measured, and an example of an allergen is described as a substance that is immobilized as a binding substance in the immobilization region 25. The invention is not limited to this, and the substance to be measured is, for example, a genotype derived from human papillovirus (HPV), and is immobilized on the immobilization region 32c of the second base 32 as a binding substance. Alternatively, a genomic DNA probe derived from HPV can be used. In this case, 13 high-risk types such as type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, etc. It is also possible to construct an assay system for detecting classified HPV.

また、本発明は、例えば、手術前感染症検査マーカー、肝機能検査マーカー、腎機能検査マーカー、自己免疫性肝炎マーカー、心疾患マーカー、敗血症マーカー、甲状腺マーカー、又は血中に含まれる特定の薬物等を測定対象物質とすることも可能である。 The present invention also provides, for example, preoperative infection test markers, liver function test markers, renal function test markers, autoimmune hepatitis markers, heart disease markers, sepsis markers, thyroid markers, or specific drugs contained in blood. etc. can also be used as substances to be measured.

ここで、表1には、(1)手術前感染症検査マーカーとして、Syphilis TP, HIV Ag/Ab combo,Anti-HCV,HBsAgを、(2)肝機能検査マーカーとして、Anti-HBc,Anti-HBs,Anti-HBe,HBeAg,Anti-HBc IgMを、(3)腎機能検査マーカーとして、BUN,CRE,UAを、(4)自己免疫性肝炎マーカーとして、IgG,抗核抗体を、(5)心疾患マーカーとして、トロポニン,ミオグロビン,CK-MB等の生化学的心筋マーカー, 心臓型脂肪酸結合蛋白を、(6)敗血症マーカーとして、Procalcitonin,Presepsinを、(7)アレルギー(アレルゲン)の典型例として、ハウスダスト,ヤケヒョウダニ,ネコ皮膚,卵白,コナヒョウダニ,ミルク,小麦,大豆,ヒノキ,スギを、(8)甲状腺マーカーとして、TSH,Free T4, TRAbを、(9)血中に含まれる特定の薬物として、VCM,TEIC,ABKを上記測定法にて評価した結果を示している。表1中において、コントロール(測定対象物質が無い状態)と比較して優位な比色シグナルが認められた測定対象物質を「陽性」として評価し、「陽性」とまではいかないまでもコントロールに対して優位差が認められた測定対象物質を「疑陽性」として評価した。 Here, Table 1 shows (1) Syphilis TP, HIV Ag/Ab combo, Anti-HCV, and HBsAg as preoperative infection test markers, and (2) Anti-HBc and Anti-HBc as liver function test markers. HBs, Anti-HBe, HBeAg, Anti-HBc IgM, (3) BUN, CRE, UA as renal function test markers, (4) IgG, antinuclear antibody as autoimmune hepatitis markers, (5) (6) Procalcitonin and Presepsin as sepsis markers; , house dust, house dust mite, cat skin, egg white, Dermatophagoides mite, milk, wheat, soybean, cypress, cedar, (8) TSH, Free T4, TRAb as thyroid markers, (9) specific drugs contained in blood , the results of evaluating VCM, TEIC, and ABK by the above measurement method are shown. In Table 1, the substance to be measured that gave a superior colorimetric signal compared to the control (without the substance to be measured) was evaluated as “positive”, and even if it was not “positive”, it was Substances to be measured for which a superior difference was observed in the results were evaluated as “false positives.”

また、図11には、(1)手術前感染症検査マーカー(1.Syphilis TP, 2.HIV Ag/Ab combo,3.Anti-HCV,4.HBsAg)、(2)肝機能検査マーカー(1.Anti-HBc,2.Anti-HBs,3.Anti-HBe,4.HBeAg,5.Anti-HBc IgM)、(3)腎機能検査マーカー(1.BUN,2.CRE,3.UA)、(4)自己免疫性肝炎マーカー(1.IgG,2.抗核抗体)、及び(5)心疾患マーカー(1.トロポニン,2.ミオグロビン,3.CK-MB等の生化学的心筋マーカー,4.心臓型脂肪酸結合蛋白)のそれぞれを測定した際に得られた比色スポットの発色状態を示した。図12には、(6)敗血症マーカー(1.Procalcitonin,2.Presepsin)、(7)アレルギー(アレルゲン)の典型例(1.ハウスダスト,2.ヤケヒョウダニ,3.ネコ皮膚,4.卵白,5.コナヒョウダニ,6.ミルク,7.小麦,8.大豆,9.ヒノキ,10.スギ)、(8)甲状腺マーカー(1.TSH,2.Free T4, 3.TRAb)、及び(9)血中に含まれる特定の薬物(1.VCM,2.TEIC,3.ABK)のそれぞれを測定した際に得られた比色スポットの発色状態を示した。 In addition, FIG. 11 shows (1) preoperative infection test markers (1. Syphilis TP, 2. HIV Ag/Ab combo, 3. Anti-HCV, 4. HBsAg), (2) liver function test markers (1 (3) renal function test markers (1.BUN, 2.CRE, 3.UA), (4) autoimmune hepatitis markers (1. IgG, 2. antinuclear antibody), and (5) cardiac disease markers (1. troponin, 2. myoglobin, 3. biochemical myocardial markers such as CK-MB, 4 . heart-type fatty acid-binding protein) are shown in the color development of the colorimetric spots obtained when measuring each of them. Figure 12 shows (6) sepsis markers (1. Procalcitonin, 2. Presepsin), (7) typical examples of allergies (allergens) (1. house dust, 2. house dust mite, 3. cat skin, 4. egg white, 5 (8) thyroid markers (1. TSH, 2. Free T4, 3. TRAb), and (9) blood The color development state of the colorimetric spots obtained when each of the specific drugs (1.VCM, 2.TEIC, 3.ABK) contained in is measured is shown.

Figure 0007205940000001
Figure 0007205940000001

表1及び図11並びに図12に示されるように、(1)手術前感染症検査マーカーにおける2.HIV Ag/Ab combo及び4.HBsAgと、(7)アレルギー(アレルゲン)の典型例における、4.卵白、6.ミルク、7.小麦、8.大豆、及び9.ヒノキ等の一部のものについては疑陽性との結果であったが、今回測定対象としたその他全ての項目については、コントロールと比較して優位な比色シグナルが認められた。これらの結果から、本発明に係る固相反応チップを用いた測定系は、測定対象の適用種目を選ばず、所謂、スクリーニング検査に適した測定系であることが示された。 As shown in Table 1 and Figures 11 and 12, (1) 2. in preoperative infection test markers HIV Ag/Ab combo and 4. HBsAg, and (7) typical examples of allergies (allergens), 4. 6. egg white; milk;7. 8. wheat; soybeans; and9. Although the result was false positive for some items such as cypress, superior colorimetric signals were observed compared to the control for all other items that were measured this time. From these results, it was shown that the measurement system using the solid phase reaction chip according to the present invention is suitable for so-called screening tests regardless of the type of measurement target.

このような広範囲な適用範囲を備えた本発明に係る固相反応チップによれば、肝機能検査マーカーとして用いられる、AST(GOT),ALT(GPT),γ-GTPのような上記検査マーカー以外の同一疾患に対する検査マーカーへの適用や、肝臓がん、胃がん、子宮がん、食道がん、腎がん、すい臓がん、前立腺がん、大腸がん、肺がんといった各種癌マーカー、出血熱、重症急性呼吸器症候群、中東呼吸器症候群、鳥インフルエンザ、細菌性赤痢、E型肝炎、A型肝炎、インフルエンザ、ウィルス性肝炎、急性膜炎等の1種感染症から5種感染症、新型インフルエンザ等感染症、指定感染症、新感染症等の感染症マーカー、又は白血球、C型反応性蛋白質、血清アミロイドA蛋白質といった炎症マーカー等の上記以外の疾患検査マーカーへの応用も期待することができる。 According to the solid-phase reaction chip according to the present invention, which has such a wide range of application, other than the test markers such as AST (GOT), ALT (GPT), and γ-GTP, which are used as liver function test markers, as test markers for the same disease, various cancer markers such as liver cancer, stomach cancer, uterine cancer, esophageal cancer, kidney cancer, pancreatic cancer, prostate cancer, colon cancer, lung cancer, hemorrhagic fever, Severe acute respiratory syndrome, Middle East respiratory syndrome, bird flu, bacillary dysentery, hepatitis E, hepatitis A, influenza, viral hepatitis, acute meningitis, etc. Application to infectious disease markers such as infectious diseases, designated infectious diseases, and new infectious diseases, or inflammatory markers such as leukocytes, type C-reactive protein, and serum amyloid A protein, is also expected to be applied to disease test markers other than those described above.

更には、上記疾患関連の検査マーカーのみならず、本発明は、例えば、殺虫剤、殺ダニ剤、殺線虫剤、殺菌剤、除草剤、殺虫殺菌剤、殺そ剤、植物成長調整剤、忌避剤、誘引剤、展着剤といった農薬や、興奮剤、麻薬性鎮痛剤、蛋白質同化剤、利尿剤、ペプチド及び糖蛋白ホルモンとその同族体、血液ドーピング、アルコール、マリファナ、局所麻酔剤、コルチコステロイド(副腎皮質ステロイド)、ベータ遮断剤といったドーピング薬物の検査・測定への展開も考えられる。 Furthermore, in addition to the above disease-related test markers, the present invention also includes, for example, insecticides, acaricides, nematicides, fungicides, herbicides, insecticide fungicides, rodenticides, plant growth regulators, repellents. pesticides, attractants, spreading agents, stimulants, narcotic analgesics, anabolic agents, diuretics, peptide and glycoprotein hormones and their congeners, blood doping, alcohol, marijuana, local anesthetics, cortico It is also possible to develop the test and measurement of doping drugs such as steroids (adrenal corticosteroids) and beta-blockers.

これまでの説明においては、本発明に係る固相チップを用いた測定方法の好適な例として、測定対象物質に対して特異的結合能の有し酵素活性を備えた生理活性物質を用いた例について説明した。酵素標識を用いた測定系は、反応特異性及びシグナル増幅といった観点からしても優れた測定系である。しかしながら、酵素は分子量が大きい為、例えば抗原-抗体反応に影響を与えたり、酵素が失活すると測定系として機能しなくなるといった問題があり、これらが要因となってシグナル強度が安定せず、測定の再現性が低下することがあった。本発明に係る固相反応チップは、酵素以外のシグナル生成物質により標識された標識化物質を用いた測定系を構築することも可能であるため、以下に説明する。 In the above description, as a preferred example of the measurement method using the solid-phase chip according to the present invention, an example using a physiologically active substance having an ability to specifically bind to the substance to be measured and having enzymatic activity is used. explained. A measurement system using an enzyme label is an excellent measurement system from the viewpoint of reaction specificity and signal amplification. However, since enzymes have large molecular weights, there are problems such as affecting the antigen-antibody reaction, and deactivation of the enzymes causing the system to cease functioning as a measurement system. The reproducibility of was sometimes lowered. Since the solid-phase reaction chip according to the present invention can also construct a measurement system using a labeling substance labeled with a signal-generating substance other than an enzyme, it will be described below.

酵素以外のシグナル生成物質により標識された標識化物質を用いた測定方法は、固相反応チップに対して、開口部を介して検体液を導入し、測定対象物質と固定化部に固定化された結合物質とを結合させる第1の結合ステップと、測定対象物質に対して特異的結合能を有し、シグナル生成物質により標識された標識化物質を第1の結合ステップにて結合物質に結合した測定対象物質に結合させる第2の結合ステップと、シグナル生成物質により生じたシグナルを測定する測定ステップとを備えることを特徴とするものである。この場合、各ステップ間又は何れかのステップ間に洗浄液を添加し固相反応チップを所定の回転数で回転させることで当該洗浄液を除去する洗浄ステップを設けてもよい。ここで、測定対象物質に対して特異的結合能を有し、シグナル生成物質により標識された標識化物質としては、放射性同位元素、ランタノイド元素、フリーラジカル誘導体、化学発光物質又は蛍光発光物質の何れかで標識された抗体、プロテインA/G、レクチン、アビジン、ストレプトアビジン等のタンパク質、核酸、又はこれらの断片を用いることができる。シグナル生成物質の標識化物質への結合は、特に限定されず、共有結合、イオン結合、水素結合、配位結合、物理吸着又は化学吸着等を挙げることができる。また、シグナル生成物質と標識化物質との間での非特異的吸着を防ぐために、例えば、ポリエチレングリコール鎖等の有機分子からなるリンカーを設けてもよい。なお、先の説明と同様に、測定対象物質がIgE抗体である場合、標識化抗体は、放射性同位元素、ランタノイド元素、フリーラジカル誘導体、化学発光物質又は蛍光発光物質の何れかで標識された抗IgE抗体を用いることが好ましい。 In the measurement method using a labeling substance labeled with a signal-generating substance other than an enzyme, the sample liquid is introduced through the opening of the solid-phase reaction chip, and the substance to be measured and the immobilization portion are immobilized. a first binding step of binding the binding substance to the binding substance; and a measuring step of measuring the signal generated by the signal-generating substance. In this case, a washing step may be provided in which a washing liquid is added between each step or any of the steps and the washing liquid is removed by rotating the solid-phase reaction chip at a predetermined number of rotations. Here, the labeled substance having specific binding ability to the substance to be measured and labeled with the signal-generating substance includes any of radioisotopes, lanthanide elements, free radical derivatives, chemiluminescent substances and fluorescent luminescent substances. Proteins such as antibodies, protein A/G, lectins, avidin, and streptavidin labeled with , nucleic acids, or fragments thereof can be used. The binding of the signal-generating substance to the labeling substance is not particularly limited, and examples include covalent bond, ionic bond, hydrogen bond, coordinate bond, physical adsorption, chemical adsorption, and the like. Moreover, in order to prevent non-specific adsorption between the signal-generating substance and the labeling substance, a linker composed of an organic molecule such as a polyethylene glycol chain may be provided. As in the above description, when the substance to be measured is an IgE antibody, the labeled antibody is an antibody labeled with either a radioactive isotope, a lanthanide element, a free radical derivative, a chemiluminescent substance, or a fluorescent substance. Preferably, IgE antibodies are used.

シグナル生成物質として放射性同位元素を用いる場合、例えば、125I、131I、H等を挙げることでき、感度、半減期の観点から125Iを用いることが好ましい。ヨウ素は酸化すると新電子試薬として抗体(タンパク質)中のチロシン残基、ヒスチジン残基等と容易に結合するため、標識化には好適である。When a radioactive isotope is used as a signal-generating substance, for example, 125 I, 131 I, 3 H, etc. can be mentioned, and 125 I is preferably used from the viewpoint of sensitivity and half-life. When oxidized, iodine readily binds to tyrosine residues, histidine residues, etc. in antibodies (proteins) as a new electron reagent, and is thus suitable for labeling.

シグナル生成物質としてランタノイド元素を用いる場合、原子番号57~71までの元素(La、Ce、Pr、Nd、Pm、Sm、Eu、Gd、Tb、Dy、Ho、Er、Tm、Yb、Lu)を挙げることができる。この中でも、原子番号63番のEu(ユーロピウム)のキレートは、励起光(340nm)と放射光(615nm)との波長差が大きく、また放射光(蛍光)寿命が長いため時間分解蛍光測定を行うことができる。 When using a lanthanide element as a signal-generating substance, elements with atomic numbers from 57 to 71 (La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu) can be mentioned. Among them, Eu (Europium) chelate with atomic number 63 has a large wavelength difference between the excitation light (340 nm) and the synchrotron radiation (615 nm), and the synchrotron radiation (fluorescence) lifetime is long, so time-resolved fluorescence measurement is performed. be able to.

シグナル生成物質としてフリーラジカル誘導体を用いる場合、例えば、ピペリジン-N-オキシド誘導体、ピロリヂン-N-オキシド誘導体、オキサゾリジン-N-オキシド誘導体等を挙げることができ、これらのフリーラジカル誘導体で標識した標識化抗体のESRスペクトル変化を指標として測定する。 When a free radical derivative is used as a signal-generating substance, examples thereof include piperidine-N-oxide derivatives, pyrrolidine-N-oxide derivatives, oxazolidine-N-oxide derivatives, etc. Labeling labeled with these free radical derivatives The ESR spectrum change of the antibody is measured as an index.

シグナル生成物質として化学発光物質を用いる場合、例えば、ルミノール誘導体、アクリジニウム塩類、ジオキセタン類、ルシフェリン、ルシゲニン、塩化オキザリル、インドキシル誘導体等を挙げることができ、これらの化学発光物質で標識した標識化抗体を、例えば、マイクロペルオキシダーゼ、ペルオキシターゼといった酵素、H共存下又はアルカリ条件、H共存下で化学発光反応させ、これを測定する。When a chemiluminescent substance is used as a signal-generating substance, examples thereof include luminol derivatives, acridinium salts, dioxetanes, luciferin, lucigenin, oxalyl chloride, indoxyl derivatives, etc. Labeled antibodies labeled with these chemiluminescent substances is subjected to a chemiluminescence reaction in the presence of enzymes such as microperoxidase and peroxidase in the presence of H 2 O 2 or under alkaline conditions in the presence of H 2 O 2 and measured.

シグナル生成物質として蛍光発光物質を用いる場合、蛍光色素、量子ドット、又は蛍光色素若しくは量子ドットと粒子とからなる蛍光性粒子(ビーズ)の何れかを挙げることができる。なお、ここでいう蛍光発光物質は、200nm~700nmの範囲内の波長の紫外光~近赤外光により励起されたときに、400nm~1100nmの範囲内の波長の可視光~近赤外光の放射光(発光)を示すものである。 When a fluorescent light-emitting substance is used as the signal-generating substance, any of fluorescent dyes, quantum dots, or fluorescent particles (beads) composed of fluorescent dyes or quantum dots and particles can be used. In addition, the fluorescence-emitting substance referred to here is a visible light to near-infrared light having a wavelength within the range of 400 nm to 1100 nm when excited by ultraviolet light to near-infrared light having a wavelength within the range of 200 nm to 700 nm. It shows synchrotron radiation (luminescence).

蛍光色素の例としては、フルオレセイン系色素分子、ローダミン系色素分子、ALexa Fluor(インビトロジェン社製)系色素分子、BODIPY(インビトロジェン社製)系色素分子、カスケード系色素分子、クマリン系色素分子、エオジン系色素分子、NBD系色素分子、ピレン系色素分子、シアニン系色素分子、芳香族炭化水素系分子等を挙げることができる。 Examples of fluorescent dyes include fluorescein-based dye molecules, rhodamine-based dye molecules, ALexa Fluor (manufactured by Invitrogen)-based dye molecules, BODIPY (manufactured by Invitrogen)-based dye molecules, cascade-based dye molecules, coumarin-based dye molecules, and eosin-based dye molecules. Examples include dye molecules, NBD-based dye molecules, pyrene-based dye molecules, cyanine-based dye molecules, aromatic hydrocarbon-based molecules, and the like.

具体的には、5-カルボキシ-フルオレセイン、6-カルボキシ-フルオレセイン、5,6-ジカルボキシ-フルオレセイン、6-カルボキシ-2’,4,4’,5’,7,7’-ヘキサクロロフルオレセイン、6-カルボキシ-2’,4,7,7’-テトラクロロフルオレセイン、6-カルボキシ-4’,5’-ジクロロ-2’,7’-ジメトキシフルオレセイン、ナフトフルオレセイン、5-カルボキシ-ローダミン、6-カルボキシ-ローダミン、5,6-ジカルボキシ-ローダミン、ローダミン 6G,テトラメチルローダミン、X-ローダミン、スルホローダミンB、スルホローダミン101、及びALex Fluor 350、ALex Fluor 405、ALex Fluor 430、ALex Fluor 488、ALex Fluor 500、ALex Fluor 514、ALex Fluor 532、ALex Fluor 546、ALex Fluor 555、ALex Fluor 568、ALex Fluor 594、ALex Fluor 610、ALex Fluor 633、ALex Fluor 635、ALex Fluor 647、ALex Fluor 660、ALex Fluor 680、ALex Fluor 700、ALex Fluor 750、BODIPY FL、BODIPY TMR、BODIPY 493/503、BODIPY 530/550、BODIPY 558/568、BODIPY 564/570、BODIPY 576/589、BODIPY 581/591、BODIPY 630/650、BODIPY 650/665(以上、インビトロジェン社製)、メトキシクマリン、エオジン、NBD、ピレン、Cy5、Cy5.5、Cy7、HiLyte Fluor(登録商標、アナスペック社製)、Dylight 594(登録商標、サーモサイエンティフィック社製)系色素分子、ATTO 594(登録商標、ATTO-TEC社製)、MFP 594(登録商標、Mobitec社製)、5,10,15,20-テトラフェニルポルフィンテトラスルホン酸、亜鉛5,10,15,20-テトラフェニルポルフィンテトラスルホン酸、フタロシアニンテトラスルホン酸、亜鉛フタロシアニンテトラスルホン酸、N,N-Bis(2,6-diisopropylphenyl)-1,6,7,12-(4-tert-butyl-phenoxy)-perylen-3,4,9,10-tetracarbonacid diimide、N,N-Bis(2,6-diisopropylphenyl)-1,6,7,12-(4-tert-butyl-phenoxy)-perylen-3,4,9,10-tetracarboxdiimide、Benzensulfonic acid、4,4‘,4’‘,4’‘’-[(1,3,8,10-tetrahydro-1,3,8,10-tetraoxoperylo[3,4-cd:9,10-c‘d’]dipyran-5,6,12,13-tetrayl)tetralis(oxy)]tetrakis等に加え、メロシアニン、有機窒素化合物であるアクリジン、ピラニン、ピロメテン、ルシフェリン、DCM(4-(ジシアノメチレン)-2-メチル-6-(4-ジメチルアミノスチリル)-4H-ピラン)、スチルベンといったものも挙げることができる。なお、これらの蛍光色素は単独で使用してもよいし、複数種を組み合わせてもよい。 Specifically, 5-carboxy-fluorescein, 6-carboxy-fluorescein, 5,6-dicarboxy-fluorescein, 6-carboxy-2′,4,4′,5′,7,7′-hexachlorofluorescein, 6 -carboxy-2',4,7,7'-tetrachlorofluorescein, 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein, naphthofluorescein, 5-carboxy-rhodamine, 6-carboxy - rhodamine, 5,6-dicarboxy-rhodamine, rhodamine 6G, tetramethylrhodamine, X-rhodamine, sulforhodamine B, sulforhodamine 101 and ALex Fluor 350, ALex Fluor 405, ALex Fluor 430, ALex Fluor 488, ALex Fluor 500、ALex Fluor 514、ALex Fluor 532、ALex Fluor 546、ALex Fluor 555、ALex Fluor 568、ALex Fluor 594、ALex Fluor 610、ALex Fluor 633、ALex Fluor 635、ALex Fluor 647、ALex Fluor 660、ALex Fluor 680、 ALex Fluor 700、ALex Fluor 750、BODIPY FL、BODIPY TMR、BODIPY 493/503、BODIPY 530/550、BODIPY 558/568、BODIPY 564/570、BODIPY 576/589、BODIPY 581/591、BODIPY 630/650、BODIPY 650/665 (manufactured by Invitrogen), methoxycoumarin, eosin, NBD, pyrene, Cy5, Cy5.5, Cy7, HiLyte Fluor (registered trademark, manufactured by Anaspec), Dylight 594 (registered trademark, Thermo Scientific company) dye molecules, ATTO 594 (registered trademark, manufactured by ATTO-TEC), MFP 594 (registered trademark, manufactured by Mobitec), 5,10,15,20-tetraphenylporphinetetrasulfonic acid, zinc 5,10 , 15,20-tetraphenylporphinetetrasulfonic acid, phthalocyaninetetrasulfo acid, zinc phthalocyaninetetrasulfonic acid, N,N-Bis(2,6-diisopropylphenyl)-1,6,7,12-(4-tert-butyl-phenyl)-perylene-3,4,9,10- 4 , 4′,4″,4′″-[(1,3,8,10-tetrahydro-1,3,8,10-tetraoxoperylo[3,4-cd:9,10-c′d′] In addition to dipyran-5,6,12,13-tetrayl) tetralis (oxy)] tetrakis and the like, merocyanine, organic nitrogen compounds acridine, pyranine, pyromethene, luciferin, DCM (4-(dicyanomethylene)-2-methyl- 6-(4-dimethylaminostyryl)-4H-pyran), stilbenes, etc. may also be mentioned. In addition, these fluorescent dyes may be used singly or in combination.

量子ドットの例としては、II-VI族化合物、III-V族化合物、IV族元素等を含有する量子ドットを用いることができ、これらの化合物は単独で使用してもよいし、複数種を組み合わせてもよい。 Examples of quantum dots include quantum dots containing group II-VI compounds, group III-V compounds, group IV elements, and the like, and these compounds may be used singly or in combination. May be combined.

具体的には、CdSe、CdS、CdTe、ZnSe、ZnS、ZnTe、InP、InN、InAs、InGaP、GaAs、Si、Ge等を挙げることができる。なお、これらの量子ドットをコアとし、他のナノ材料でシェル化したコア/シェル型量子ドットを調整し、さらにその表面をポリエチレングリコールや両親媒性のポリマー等の生体親和性の高い有機物質で被覆したものも本発明では用いることが可能である。 Specific examples include CdSe, CdS, CdTe, ZnSe, ZnS, ZnTe, InP, InN, InAs, InGaP, GaAs, Si, Ge, and the like. In addition, we prepared a core/shell type quantum dot in which these quantum dots were used as the core and shelled with other nanomaterials, and furthermore, the surface was coated with organic substances with high biocompatibility such as polyethylene glycol and amphiphilic polymers. A coated one can also be used in the present invention.

蛍光色素若しくは量子ドットと粒子とからなる蛍光性粒子の例としては、シリカ、アルミナといった無機粒子又はポリスチレン、ポリ(メタ)アクリル酸エステルといった有機ポリマーからなる樹脂粒子(樹脂重合体)に上記例示した蛍光色素、量子ドットの何れかが結合、一部結合、又は粒子内部に封入されたものを挙げることができる。樹脂粒子に対する蛍光色素等の導入方法については、特に限定はなく、樹脂の原料であるモノマーに蛍光色素を結合させた後にモノマーを重合させる方法、重合体を形成した後に該重合体に蛍光色素を結合させる方法、モノマーと蛍光色素とを混合して重合と蛍光色素の結合を同時に行う方法、蛍光色素自体に樹脂重合性を持たせる方法等を採用することができる。蛍光性粒子の平均粒子径は、免疫反応時に影響を与えることなく、又十分な輝度が得られるサイズであれば、特に限定はないが、1nm~100μmの範囲とすることが好ましい。なお、蛍光性粒子の例としては、紫外光~近赤外光により励起されたときに、可視光~近赤外光の放射光(発光)を放射する性質の蛍光物質と粒子との組合せであれば、特に制限されることはなく、例えば、上記のランタノイド元素と樹脂粒子との組み合わせであっても構わない。 Examples of fluorescent particles composed of fluorescent dyes or quantum dots and particles include inorganic particles such as silica and alumina, and resin particles (resin polymers) composed of organic polymers such as polystyrene and poly(meth)acrylic acid ester. Examples include those in which either fluorescent dyes or quantum dots are bonded, partially bonded, or encapsulated inside particles. The method of introducing the fluorescent dye into the resin particles is not particularly limited, and may be a method of binding the fluorescent dye to the monomer that is the raw material of the resin and then polymerizing the monomer, or a method of forming a polymer and then adding the fluorescent dye to the polymer. A method of binding, a method of mixing a monomer and a fluorescent dye to perform polymerization and binding of the fluorescent dye at the same time, a method of imparting resin polymerizability to the fluorescent dye itself, and the like can be employed. The average particle size of the fluorescent particles is not particularly limited as long as it does not affect the immune reaction and provides sufficient brightness, but is preferably in the range of 1 nm to 100 μm. An example of the fluorescent particles is a combination of particles and a fluorescent material that emits visible to near-infrared radiant light (luminescence) when excited by ultraviolet to near-infrared light. There is no particular limitation, and for example, a combination of the above lanthanoid element and resin particles may be used.

本発明で用いることができる蛍光性粒子は、公知の方法により作成することが可能であるし、市販されている蛍光性粒子を用いてもよい。例えば、特許文献3には、樹脂からなる樹脂粒子に蛍光色素が共有結合以外で結合された蛍光色素標識用樹脂粒子の合成方法について記載がなされており、所望の蛍光色素を用いることで種々の蛍光性粒子を作成することができる。 Fluorescent particles that can be used in the present invention can be prepared by a known method, and commercially available fluorescent particles may be used. For example, Patent Document 3 describes a method for synthesizing resin particles for fluorescent dye labeling, in which a fluorescent dye is bound to a resin particle made of a resin other than by a covalent bond. Fluorescent particles can be made.

また、近年、樹脂粒子に封入された蛍光色素の自己消光(濃度消光)に対する解決策として凝集誘発発光活性を有する物質に注目が集まっている。特許文献4には、1,1-ジメチル-2,3,4,5-テトラフェニルシロール内包ポリスチレン微粒子、1,1,2,3,4,5-ヘキサフェニルシロール内包ポリスチレン微粒子、1,1-ジメチル-2,5-ジアニシル-3,4-ジフェニルシロール内包ポリスチレン微粒子、1,1,2,3,4,5-ヘキサフェニルシロール内包ポリスチレン微粒子といった網状ポリマーからなる粒子であって、凝集誘発発光活性化合物(シロール)を包含する蛍光樹脂微粒子について記載がなされている。凝集誘発発光活性化合物としては、シロール以外にも、例えば、テトラフェニルエチレン誘導体等も知られており、これらの化合物が網状ポリマーに内包されて構成された蛍光樹脂微粒子を本発明に係る蛍光性粒子として用いることで、従来のπ共役系蛍光物質を用いた場合よりも高効率に測定が可能となることが期待される。 Further, in recent years, attention has been focused on substances having aggregation-induced luminescence activity as a solution to self-quenching (concentration quenching) of fluorescent dyes encapsulated in resin particles. Patent Document 4 discloses 1,1-dimethyl-2,3,4,5-tetraphenylsilole-encapsulating polystyrene fine particles, 1,1,2,3,4,5-hexaphenylsilole-encapsulating polystyrene fine particles, 1,1- Particles made of a network polymer such as dimethyl-2,5-dianisyl-3,4-diphenylsilol-encapsulating polystyrene fine particles and 1,1,2,3,4,5-hexaphenylsilole-encapsulating polystyrene fine particles, which exhibit aggregation-induced luminescence activity Fluorescent resin microparticles containing compounds (siloles) are described. In addition to siloles, for example, tetraphenylethylene derivatives and the like are also known as aggregation-induced luminescence active compounds. , it is expected that the measurement can be performed with higher efficiency than when using conventional π-conjugated fluorescent materials.

このように、放射性同位元素、ランタノイド元素、フリーラジカル誘導体、化学発光物質又は蛍光発光物質の何れかのシグナル生成物質により標識された標識化物質を用いることにより、酵素活性を測定する系と同程度又はそれ以上の高効率な測定系を構築することができる。また、シグナル生成物質として放射性同位元素、ランタノイド元素、フリーラジカル誘導体、又は蛍光発光物質を用いた場合、酵素活性を測定する系とは異なり、測定ステップにて基質(溶液)を添加する手間を省くことが可能であるため、より迅速で再現性の高い測定を行うことができる。 In this way, by using a labeling substance labeled with a signal-generating substance such as a radioactive isotope, a lanthanide element, a free radical derivative, a chemiluminescent substance, or a fluorescent luminescent substance, it is possible to achieve the same extent as in a system for measuring enzyme activity. Or a more efficient measurement system can be constructed. In addition, when a radioactive isotope, a lanthanoid element, a free radical derivative, or a fluorescence-emitting substance is used as a signal-generating substance, unlike a system for measuring enzyme activity, there is no need to add a substrate (solution) in the measurement step. This allows for faster and more reproducible measurements.

[変形例]
上記実施形態の説明においては、固定化部23が備える4つの固定化領域25の外縁部28において、内角度が90°である1つの頂点を有し、固定化部23全体の平面視形状が四角形状の例について説明した。しかしながら、本発明は当該形状に限定されるものではなく、例えば、固定化部全体の平面視形状として三角形状のもの、八角形状のものといった他の多角形状等の変形例が可能である。図8(a)は、開口部141及び固定化部対峙面131が形成された上蓋部材101の例であり、図8(b)は上蓋部材101と嵌合可能であり、3つの固定化領域251のそれぞれの外縁部に内角度が60°である1つの頂点232が設けられ、全体の平面視形状として三角形状を有する固定化部231を備えた下蓋部材301の構成例である。また、図9(a)は、開口部142及び固定化部対峙面132が形成された上蓋部材102の例であり、図9(b)は上蓋部材102と嵌合可能であり、4つの固定化領域252のそれぞれの外縁部に内角度が135°である2つの頂点234が設けられ、全体の平面視形状として八角形状を有する固定化部233を備えた下蓋部材302の構成例である。なお、図4、図8、及び図9で示した例は一例に過ぎず、本発明では、頂点内角度、頂点数、当該頂点を構成する辺数、辺長さの比、直線又曲線といった辺の線種等は適宜選択可能であり、これらの選択に基づき固定化部表面に形成される固定化領域の個数にも制限はない。
[Modification]
In the description of the above embodiment, the outer edge portions 28 of the four immobilization regions 25 included in the immobilization portion 23 have one vertex with an inner angle of 90°, and the planar view shape of the immobilization portion 23 as a whole is A rectangular example has been described. However, the present invention is not limited to this shape, and for example, other polygonal shapes, such as a triangular shape and an octagonal shape, are possible as the planar view shape of the entire fixing portion. FIG. 8(a) shows an example of the upper lid member 101 in which the opening 141 and the fixing portion facing surface 131 are formed, and FIG. 251 is provided with one vertex 232 having an inner angle of 60° on each outer edge portion, and is a configuration example of the lower lid member 301 provided with the fixing portion 231 having a triangular shape as an overall planar view. 9A shows an example of the upper lid member 102 in which the opening 142 and the fixing portion facing surface 132 are formed, and FIG. 10 is a structural example of a lower lid member 302 including a fixing portion 233 having two vertices 234 with an inner angle of 135° on each outer edge of a fixing region 252 and having an octagonal shape as a whole in plan view. . The examples shown in FIGS. 4, 8, and 9 are only examples, and in the present invention, there are The line type of the side can be selected as appropriate, and the number of immobilization regions formed on the surface of the immobilization portion is not limited based on these selections.

さらに、本発明では、上蓋部材及び下蓋部材が嵌合一体化した形状も適宜変更可能である。例えば、図10(a)に示すように、平面視形状が四角形状の上蓋部材103及び下蓋部材303が嵌合一体化した固相反応チップ50や、図10(b)で示すように、平面視形状が六角形の上蓋部材104及び下蓋部材304が嵌合一体化した固相反応チップ60といった組み合わせも可能である。これらの固定化部並びに蓋部材の組合せについては、測定精度の高さ、再現性、製造の容易さ、製造コスト等の諸条件を鑑み適宜選択することが可能である。 Furthermore, in the present invention, the shape in which the upper lid member and the lower lid member are fitted together can be changed as appropriate. For example, as shown in FIG. 10(a), a solid-phase reaction chip 50 in which an upper cover member 103 and a lower cover member 303 having a square shape in plan view are fitted and integrated, or as shown in FIG. A combination of the solid-phase reaction chip 60 in which the upper lid member 104 and the lower lid member 304 having a hexagonal shape in plan view are fitted and integrated is also possible. The combination of the immobilized portion and the lid member can be appropriately selected in consideration of various conditions such as high measurement accuracy, reproducibility, ease of manufacture, and manufacturing cost.

以上のように、本発明によれば、従来必要であったカバー部材を廃し、結合物質を固定化する固定化領域の外縁部において少なくとも1つの頂点を有するように構成することで、内部に吸液部材を備えた固相反応チップの欠点を克服し、迅速に且つ簡便な操作で検体液中に含まれる測定対象物質を精度よく検出することが可能な固相反応チップ及びこれを用いた測定方法を提供することができる。 As described above, according to the present invention, the cover member that was conventionally required is abolished, and the immobilization region for immobilizing the binding substance is configured to have at least one vertex at the outer edge thereof, so that the binding substance can be absorbed inside. A solid-phase reaction chip capable of overcoming the drawbacks of solid-phase reaction chips equipped with a liquid component and capable of detecting a substance to be measured contained in a sample liquid with high accuracy by rapid and simple operation, and measurement using the same can provide a method.

10、101、102、103、104 上蓋部材,11、21 内側底面,12 上蓋嵌合壁,13、131、132 固定化部対峙面,14、141,142 開口部,20、301、302,303、304 下蓋部材,22 下蓋嵌合壁,23、231、233 固定化部,24 固定化部表面,25、251、252 固定化領域,26 隆起部,27 外周,28 外縁部,30 内部空間,40 吸液部材,50、60、100 固相反応チップ,200 自動測定装置,201 分注ユニット,202 遠心分離部,203 撮像部,204 操作部,205 画像解析部,206 測定結果生成部,207 制御部,230、232、234 頂点,250 スポット Reference Signs List 10, 101, 102, 103, 104 upper lid member 11, 21 inner bottom surface 12 upper lid fitting wall 13, 131, 132 fixing portion facing surface 14, 141, 142 opening 20, 301, 302, 303 , 304 lower lid member, 22 lower lid fitting wall, 23, 231, 233 immobilization portion, 24 immobilization portion surface, 25, 251, 252 immobilization region, 26 raised portion, 27 outer periphery, 28 outer edge portion, 30 inside Space, 40 liquid absorption member, 50, 60, 100 solid phase reaction chip, 200 automatic measurement device, 201 dispensing unit, 202 centrifugal separation section, 203 imaging section, 204 operation section, 205 image analysis section, 206 measurement result generation section , 207 control unit, 230, 232, 234 vertex, 250 spot

Claims (20)

上蓋部材と下蓋部材とが嵌合一体化することにより回転体として形成される固相反応チップであって、
前記上蓋部材又は前記下蓋部材の何れかの内側底面側に設けられ、検体液に含まれる測定対象物質に対して特異的結合能を有する複数の結合物質を固定化する固定化部と、
前記上蓋部材に設けられ、前記固定化部表面に前記検体液を供給する開口部と、
前記固定化部外側に設けられ、前記開口部を介して供給された前記検体液を吸液する吸液部とを有し、
前記固定化部は、対峙する内側底面方向側に隆起した隆起部により区分された複数の固定化領域を有し、それぞれの固定化領域にはスポットがn×n列(nは2乃至6の整数)となるように配列され、それぞれのスポットは窪みが形成されて前記結合物質が固定可能とされ、
各固定化領域の外縁部には少なくとも1つの頂点が含まれ、各固定化領域は回転対称に形成されること
を特徴とする固相反応チップ。
A solid-phase reaction chip formed as a rotating body by fitting and integrating an upper lid member and a lower lid member,
an immobilization unit provided on the inner bottom surface side of either the upper lid member or the lower lid member for immobilizing a plurality of binding substances having specific binding ability to a substance to be measured contained in a sample liquid;
an opening provided in the upper lid member for supplying the sample liquid to the surface of the immobilizing portion;
a liquid absorbing part provided outside the immobilizing part and absorbing the sample liquid supplied through the opening,
The immobilization portion has a plurality of immobilization regions separated by raised portions that protrude toward the inner bottom surface facing each other, and each immobilization region has n×n rows of spots (where n is 2 to 6). an integer), and each spot has a recess so that the binding substance can be immobilized,
A solid-phase reaction chip, wherein the outer edge of each immobilization region includes at least one vertex , and each immobilization region is formed rotationally symmetrically .
各固定化領域の平面視形状は全て同形状に形成されること
を特徴とする請求項1に記載の固相反応チップ。
2. The solid-phase reaction chip according to claim 1, wherein all of the immobilizing regions have the same planar shape.
前記スポットは100ミクロン乃至1ミリの範囲の直径を有する大きさで形成されること
を特徴とする請求項1に記載の固相反応チップ。
2. The solid-phase reaction chip according to claim 1, wherein said spot is formed with a size having a diameter ranging from 100 microns to 1 mm .
前記結合物質はI型アレルギー反応を誘発するアレルゲンであること
を特徴とする請求項1乃至請求項3の何れか1項に記載の固相反応チップ。
4. The solid phase reaction chip according to any one of claims 1 to 3, wherein the binding substance is an allergen that induces type I allergic reaction.
前記測定対象物質はアレルゲン特異的抗体であること
を特徴とする請求項4に記載の固相反応チップ。
5. The solid phase reaction chip according to claim 4, wherein the substance to be measured is an allergen-specific antibody.
前記アレルゲン特異的抗体はIgE抗体であること
を特徴とする請求項5に記載の固相反応チップ。
6. The solid phase reaction chip according to claim 5, wherein said allergen-specific antibody is an IgE antibody.
前記結合物質はヒトパピローウィルスに由来するゲノムDNAプローブであること
を特徴とする請求項1乃至請求項3の何れか1項に記載の固相反応チップ。
4. The solid phase reaction chip according to any one of claims 1 to 3, wherein the binding substance is a genomic DNA probe derived from human papillomavirus.
前記測定対象物質はヒトパピローウィルスに由来する遺伝子型であること
を特徴とする請求項7に記載の固相反応チップ。
8. The solid phase reaction chip according to claim 7, wherein the substance to be measured is a genotype derived from human papillomavirus.
前記測定対象物質は、Syphilis TP,HIV Ag/Ab combo,Anti-HCV,HBsAgから選択される手術前感染症検査マーカーであること
を特徴とする請求項1乃至請求項3の何れか1項に記載の固相反応チップ。
The substance to be measured is a preoperative infection test marker selected from Syphilis TP, HIV Ag/Ab combo, Anti-HCV, and HBsAg, according to any one of claims 1 to 3. Solid phase reaction chip as described.
前記測定対象物質は、Anti-HBc,Anti-HBs,Anti-HBe,HBeAg,Anti-HBc IgMから選択される肝機能検査マーカーであること
を特徴とする請求項1乃至請求項3の何れか1項に記載の固相反応チップ。
4. Any one of claims 1 to 3, wherein the substance to be measured is a liver function test marker selected from Anti-HBc, Anti-HBs, Anti-HBe, HBeAg, and Anti-HBc IgM. The solid-phase reaction chip described in the paragraph.
前記測定対象物質は、BUN,CRE,UAから選択される腎機能検査マーカーであること
を特徴とする請求項1乃至請求項3の何れか1項に記載の固相反応チップ。
4. The solid phase reaction chip according to any one of claims 1 to 3, wherein the substance to be measured is a renal function test marker selected from BUN, CRE, and UA.
前記測定対象物質は、IgG,抗核抗体から選択される自己免疫性肝炎マーカーであること
を特徴とする請求項1乃至請求項3の何れか1項に記載の固相反応チップ。
4. The solid phase reaction chip according to any one of claims 1 to 3, wherein the substance to be measured is an autoimmune hepatitis marker selected from IgG and antinuclear antibodies.
前記測定対象物質は、トロポニン, ミオグロビン,生化学的心筋マーカー, 心臓型脂肪酸結合蛋白から選択される心疾患マーカーであること
を特徴とする請求項1乃至請求項3の何れか1項に記載の固相反応チップ。
4. The substance to be measured according to any one of claims 1 to 3, wherein the substance to be measured is a heart disease marker selected from troponin, myoglobin, a biochemical myocardial marker, and cardiac fatty acid binding protein. Solid state reaction chip.
前記測定対象物質は、Procalcitonin,Presepsinから選択される敗血症マーカーであること
を特徴とする請求項1乃至請求項3の何れか1項に記載の固相反応チップ。
The solid phase reaction chip according to any one of claims 1 to 3, wherein the substance to be measured is a sepsis marker selected from procalcitonin and presepsin.
前記測定対象物質は、TSH,Free T4,TRAbから選択される甲状腺マーカーであること
を特徴とする請求項1乃至請求項3の何れか1項に記載の固相反応チップ。
4. The solid phase reaction chip according to any one of claims 1 to 3, wherein the substance to be measured is a thyroid marker selected from TSH, Free T4, and TRAb.
前記測定対象物質は、VCM,TEIC,ABKから選択される血中薬物であること
を特徴とする請求項1乃至請求項3の何れか1項に記載の固相反応チップ。
4. The solid phase reaction chip according to any one of claims 1 to 3, wherein the substance to be measured is a drug in blood selected from VCM, TEIC, and ABK.
請求項1乃至請求項16の何れか1項に記載の固相反応チップに対して、
前記開口部を介して前記検体液を導入し、前記測定対象物質と前記結合物質とを結合させる結合ステップと、
前記結合物質に結合した前記測定対象物質に対して特異的結合能を有し酵素活性を備えた生理活性物質を含む反応液を添加する添加ステップと、
前記開口部を介して洗浄液を導入後、固相反応チップを所定の回転数で回転させることで前記洗浄液を除去する除去ステップと、
前記生理活性物質における前記酵素活性を測定する測定ステップとを備えること
を特徴とする測定方法。
For the solid phase reaction chip according to any one of claims 1 to 16,
a binding step of introducing the specimen liquid through the opening and binding the substance to be measured and the binding substance;
an adding step of adding a reaction solution containing a physiologically active substance having a specific binding ability to the substance to be measured bound to the binding substance and having enzymatic activity;
a removing step of removing the washing liquid by rotating the solid-phase reaction chip at a predetermined number of rotations after introducing the washing liquid through the opening;
and a measuring step of measuring the enzyme activity in the physiologically active substance.
請求項1乃至請求項16の何れか1項に記載の固相反応チップに対して、
前記開口部を介して前記検体液を導入し、前記測定対象物質と前記固定化部に固定化された前記結合物質とを結合させる第1の結合ステップと、
前記測定対象物質に対して特異的結合能を有し、シグナル生成物質により標識された標識化物質を前記第1の結合ステップにて前記結合物質に結合した前記測定対象物質に結合させる第2の結合ステップと、
前記シグナル生成物質により生じたシグナルを測定する測定ステップとを備えること
を特徴とする測定方法。
For the solid phase reaction chip according to any one of claims 1 to 16,
a first binding step of introducing the sample liquid through the opening and binding the substance to be measured and the binding substance immobilized on the immobilizing portion;
A second binding step of binding a labeling substance having specific binding ability to the substance to be measured and labeled with a signal-generating substance to the substance to be measured bound to the binding substance in the first binding step; a binding step;
and a measuring step of measuring a signal generated by the signal-generating substance.
前記シグナル生成物質は、放射性同位元素、ランタノイド元素、フリーラジカル誘導体、化学発光物質又は蛍光発光物質の何れかであること
を特徴とする請求項18に記載の測定方法。
19. The method of measurement according to claim 18, wherein the signal-generating substance is any of a radioactive isotope, a lanthanide element, a free radical derivative, a chemiluminescent substance, or a fluorescent luminescent substance.
前記蛍光発光物質は、蛍光色素、量子ドット、又は蛍光色素若しくは量子ドットと粒子とからなる蛍光性粒子の何れかであること
を特徴とする請求項19に記載の測定方法。
20. The measurement method according to claim 19, wherein the fluorescent light-emitting substance is any one of a fluorescent dye, a quantum dot, or a fluorescent particle composed of a fluorescent dye or a quantum dot and a particle.
JP2021502126A 2019-02-20 2020-02-20 Solid phase reaction chip and measurement method using the same Active JP7205940B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2019028153 2019-02-20
JP2019028153 2019-02-20
JP2019113074 2019-06-18
JP2019113074 2019-06-18
PCT/JP2020/006695 WO2020171158A1 (en) 2019-02-20 2020-02-20 Solid phase reaction chip and measurement method using same

Publications (2)

Publication Number Publication Date
JPWO2020171158A1 JPWO2020171158A1 (en) 2021-12-23
JP7205940B2 true JP7205940B2 (en) 2023-01-17

Family

ID=72144476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021502126A Active JP7205940B2 (en) 2019-02-20 2020-02-20 Solid phase reaction chip and measurement method using the same

Country Status (4)

Country Link
JP (1) JP7205940B2 (en)
KR (1) KR20210127945A (en)
CN (1) CN113454462A (en)
WO (1) WO2020171158A1 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007520712A (en) 2004-02-03 2007-07-26 ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト Diagnosis of sepsis by selective measurement of Cu / Zn superoxide dismutase (Cu / ZnSOD) concentration in patient samples
JP2010032360A (en) 2008-07-29 2010-02-12 Chisso Corp Concentration measuring method of measuring target substance using magnetic particle
WO2012001972A1 (en) 2010-06-30 2012-01-05 株式会社メタボスクリーン Microchemical chip, method for producing same, and method for using same
WO2012086346A1 (en) 2010-12-22 2012-06-28 国立大学法人 岡山大学 Diagnostic method for chronic inflammatory diseases using antibody against inhibitory co-stimulatory molecules as marker
JP2015500459A (en) 2011-11-21 2015-01-05 アバクシス, インコーポレイテッド Signal amplification in lateral flow and related immunoassays
WO2015174430A1 (en) 2014-05-15 2015-11-19 タカノ株式会社 Sample analyzing apparatus
JP2016520192A (en) 2013-05-14 2016-07-11 メタボロン,インコーポレイテッド Biomarkers associated with renal function and methods of using the same
JP2016200431A (en) 2015-04-08 2016-12-01 株式会社パートナーファーム Solid phase reaction chip and measuring method using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8522388D0 (en) * 1985-09-10 1985-10-16 Lepetit Spa Receptor-antibody sandwich assay
JP2004222689A (en) * 2003-01-20 2004-08-12 Ryokusei Mes Kk Liquid layer reaction device utilizing centrifugal force
JP2011013000A (en) 2009-06-30 2011-01-20 Consonal Biotechnologies Co Ltd Method for analyzing biochip, and system for automatic analysis of the same
JP6107244B2 (en) 2013-03-08 2017-04-05 コニカミノルタ株式会社 Fluorescent dye labeling resin particles, production method thereof, and tissue immunostaining kit containing the particles
WO2018056454A1 (en) 2016-09-26 2018-03-29 国立大学法人埼玉大学 Fine fluorescent particle containing aie-active compound

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007520712A (en) 2004-02-03 2007-07-26 ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト Diagnosis of sepsis by selective measurement of Cu / Zn superoxide dismutase (Cu / ZnSOD) concentration in patient samples
JP2010032360A (en) 2008-07-29 2010-02-12 Chisso Corp Concentration measuring method of measuring target substance using magnetic particle
WO2012001972A1 (en) 2010-06-30 2012-01-05 株式会社メタボスクリーン Microchemical chip, method for producing same, and method for using same
WO2012086346A1 (en) 2010-12-22 2012-06-28 国立大学法人 岡山大学 Diagnostic method for chronic inflammatory diseases using antibody against inhibitory co-stimulatory molecules as marker
JP2015500459A (en) 2011-11-21 2015-01-05 アバクシス, インコーポレイテッド Signal amplification in lateral flow and related immunoassays
JP2016520192A (en) 2013-05-14 2016-07-11 メタボロン,インコーポレイテッド Biomarkers associated with renal function and methods of using the same
WO2015174430A1 (en) 2014-05-15 2015-11-19 タカノ株式会社 Sample analyzing apparatus
JP2016200431A (en) 2015-04-08 2016-12-01 株式会社パートナーファーム Solid phase reaction chip and measuring method using the same

Also Published As

Publication number Publication date
KR20210127945A (en) 2021-10-25
CN113454462A (en) 2021-09-28
WO2020171158A1 (en) 2020-08-27
JPWO2020171158A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
US5501949A (en) Particle bound binding component immunoassay
US5236826A (en) Immunoassay for the detection or quantitation of an analyte
CN1946999B (en) Electroluminescent illumination source for optical detection systems
US8932878B2 (en) Diagnostic test kits employing an internal calibration system
CN1675544A (en) Self-calibration system for a magnetic binding assay
CN1675545A (en) Membrane-based assay devices that utilize time-resolved fluorescence
CN103308489A (en) Laterally-flowing immunoassay method using time resolution up-converting phosphor technology
EP0248892A1 (en) Particle-bound binding component immunoassay
JP2015511706A (en) Real-time diagnostic assay using evanescent biosensor
JP6600861B2 (en) Solid phase reaction chip and measurement method using the same
JP2003066045A (en) Allergen test chip
EP2732288B1 (en) Biological microchip for the estimation of immunoglobulin e and g levels in human blood, method of assay thereof, and reagent kit comprising same
CN102301238A (en) Automatic Analyzer
CN1777813A (en) Sample preparation for colorimetric and fluorescent assays as implemented on optical analysis discs
JP7205940B2 (en) Solid phase reaction chip and measurement method using the same
JP4920173B2 (en) Calibration microarray
CN111504959B (en) C peptide rare earth fluorescent microsphere kit, detection card and preparation method thereof
CN210199121U (en) Light-activated chemiluminescence detector
WO2021025066A1 (en) Solid-phase reaction container and measurement method in which same is used
WO2021095858A1 (en) Method for measuring physiologically active substance
JP2006337077A (en) Specimen-measuring method and kit for specimen measurement
WO2021095790A1 (en) Measurement method using solid-phase reaction chip
CN216696335U (en) Adiponectin fluorescence quantitative immunochromatography reagent strip
JP2001272405A (en) Examination kit
JPWO2006028174A1 (en) Measuring apparatus and measuring method

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210608

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20210914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220803

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221222

R150 Certificate of patent or registration of utility model

Ref document number: 7205940

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150